Skip to main content

Advertisement

SpringerLink
Log in

Role of VEGF, CD105, and CD31 in the Prognosis of Colorectal Cancer Cases

  • Original Research
  • Published:
Journal of Gastrointestinal Cancer Aims and scope Submit manuscript

Abstract

Introduction

Colorectal cancer (CRC) incidence is increasing globally. It is ranked as the second most common cancer in women and the third most in men. Angiogenesis plays a significant role in the development and spread of colorectal cancer. Angiogenesis has been proposed as a prognostic marker in a variety of human neoplasms. In this regard, markers of angiogenic endothelial cells are emerging as targets for cancer therapy.

Aim of the Work

The aim of this study is to evaluate the prognostic impact of tumor angiogenesis assessed by microvessel density (MVD) counting using CD31 and CD105 along with VEGF immunostaining in colorectal cancer patients.

Methods

VEGF, CD31, and CD105 expressions were evaluated using immunohistochemical staining in 50 patients with colorectal cancer. The relationship between their expressions and clinicopathological factors and outcome of patients were analyzed.

Results

The VEGF expression (70% of the cases) correlated significantly with larger tumor size, higher grade, and advanced tumor stage (p = 0.006, p < 0.001, p < 0.001), respectively. The mean MVD was 24.2 ± VMD by CD105 (p = 0.10.65 019 for CD105, 19.2 ± 8.41 for CD31, respectively. MVD by CD31 (p = 0.023)) and was significant predictive factors for overall survival. Furthermore, the VEGF expression (p = < 0.001) was a significant predictive factor for DFS. There was a statistically significant association between the recurrence rates with both VEGF and CD105 (p < 0.001) but not significant with CD31.

Conclusion

CRC patients with high VEGF, CD105, and CD31 expression showed poor prognosis. The immunohistochemical markers could be used for stratification of patients into low-risk and high-risk groups.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Abdel Dayem HM, Abd El All HS, Kamel AA, Yossef WT, Hamma MM. Correlation of vascular endothelial growth factor expression and neovascularization with colorectal carcinoma: a pilot study. J Adenocarcinoma. 2016;1(1):5. https://doi.org/10.21767/2572-309X.10005.

    Article  Google Scholar 

  2. Abdelzaher E, El Deeb NM, Gowil AG, Yahya. Biological and demographic profile of meningiomas in a cohort of Egyptian patients: impact on tumor recurrence. Sci World J. 2013;2013:375139. https://doi.org/10.1155/2013/375139.

    Article  Google Scholar 

  3. Bendardaf R, Buhmeida A, Hilska M, et al. VEGF-1expression in colorectal cancer is associated with disease localization, stage, and long-term disease-specific survival. Anticancer Res. 2008;28(6B):3865–70.

    PubMed  Google Scholar 

  4. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 2003;3:401–410.

  5. Cammarota R, Bertolini V, Penne G. The tumor microenvironment of colorectal cancer: stromal TLR-4 expression as a potential prognostic marker. J Transl Med. 2010;8:112.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology. 2005;69:34–10.

    Article  CAS  Google Scholar 

  7. Chen YB, Wan DS, Zhan YQ, Zhou ZW, Li W, Chen G. Correlation of tumor microvessel density to metastasis and recurrence of rectal cancer. Ai Zheng. 2004;23:1203–6.

    PubMed  Google Scholar 

  8. Chung J, Braunschweig T, Hong S, et al. Assessment of vascular endothelial growth factor in formalin fixed, paraffin-embedded colon cancer specimens using a well-based reverse phase protein array. Proteome Sci. 2014;12:27.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Dallas NA, Samuel S, Xia L, et al. Endoglin (CD105): a marker of tumor vasculature and a potential target for therapy. Clin Cancer Res. 2008;14(7):1931–7. https://doi.org/10.1158/1078-0432.CCR-07-4478.

    Article  CAS  PubMed  Google Scholar 

  10. Dassoulas K, Gazouli M, Theodoropoulos M, et al. Vascular endothelial growth factor and endoglin expression in colorectal cancer. J Cancer Res Clin Oncol. 2010;136(5):703–8.

    Article  CAS  PubMed  Google Scholar 

  11. Deliu C, Ciurea P, Neagoe D, et al. Evaluation of Angiogenesis in Colorectal Cancer. Current Health Sciences. 2015;41(2).

  12. Deliu IC, Neagoe CD, Beznă M, et al. Correlations between endothelial cell markers CD31, CD34 and CD105 in colorectal carcinoma. Rom J Morphol Embryol. 2016;57(3):1025–30.

    PubMed  Google Scholar 

  13. Ferroni P, Palmirotta R, Spila A, Martini F, et al. Prognostic value of carcinoembryonic antigen and vascular endothelial growth factor tumor tissue content in colorectal cancer. Oncology. 2006;71:176–84.

    Article  CAS  PubMed  Google Scholar 

  14. Gulubova M, Vlaykova T. Prognostic significance of mast cell number and microvascular density for the survival of patients with primary colorectal cancer. J Gastroenterol Hepatol. 2009;4(7):1265–75.

    Article  Google Scholar 

  15. Hamilton SR, Vogelstein B, Kudo S, Riboli E, Nakamura S, et al. World Health Organization Classification Of Tumours: Pathology and genetics of tumors of the digestive system. Lyon: IARC Press; 2000. p. 104–143.

  16. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74.

    Article  CAS  PubMed  Google Scholar 

  17. Hashim AF, Al-Janabi AA, Mahdi LH, et al. Vascular endothelial growth factor (VEGF) receptor expression correlates with histologic grade and stage of colorectal cancer. Libyan J Med. 2010;5 https://doi.org/10.3402/ljm.v5i0.5059.

  18. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics. CA Cancer J Clin. 2009;59:225–49.

    Article  PubMed  Google Scholar 

  19. Jamshidi S, Zargaran M, Baghaei F, et al. An immunohistochemical survey to evaluate the expression of CD105 and CD34 in ameloblastoma and odontogenic keratocyst. J Dent (Shiraz). 2014;15(4):192–8.

    Google Scholar 

  20. Jung I, Gurzu S, Ranica M, et al. The differences between the endothelial area marked with CD31 and CD105 in colorectal carcinomas by computer-assisted morphometrical analysis. Romanian J Morphol Embryol. 2009;50(2):239–43.

    CAS  Google Scholar 

  21. Kannarkatt J, Joseph J, Kurniali PC, et al. Adjuvant chemotherapy for stage II colon cancer: a clinical dilemma. J Oncol Pract. 2017;13(4):233–41. https://doi.org/10.1200/JOP.2016.017210.

    Article  PubMed  Google Scholar 

  22. Khorana AA, Ryan CK, Cox C, Eberly S, et al. Vascular endothelial growth factor, CD68, and epidermal growth factor receptor expression and survival in patients with Stage II and Stage III colon carcinoma: a role for the host response in prognosis. Cancer. 2003;97:960–8.

    Article  PubMed  Google Scholar 

  23. Li C, Gardy R, Seon BK, et al. Both high intratumoral microvessel densities determined using a CD105 antibody, and elevated plasma levels of CD105 in colorectal cancer patients correlate with poor prognosis. Br J Cancer. 2003;88:1424–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Minhajat R, Mori D, Yamasaki F, et al. Endoglin (CD105) expression in angiogenesis of colon cancer: analysis using tissue microarrays and comparison with other endothelial markers. Virchows Arch. 2006;448(2):127–34. Epub 2005 Sep 22

    Article  CAS  PubMed  Google Scholar 

  25. Mohamed AH, Abd El All SH, Kamel AA, et al. Correlation of Vascular Endothelial Growth Factor Expression and Neovascularization with Colorectal Carcinoma: A Pilot Study .journal of adenocarcinoma. 2016;1(1):5

  26. Mokhtar N, Gouda I, Adel I. Cancer pathology registry (2003–2004) and time trend analysis. In: Mokhtar N, Gouda I, Adel I, editors. Malignant digestive system tumors. Cairo: NCI, Elshere press; 2007. p. 55–67.

  27. Nakayama H, Enzan H, Miyazaki E, et al. Differential expression of CD34 in normal colorectal tissue, peritumoral inflammatory tissue, and tumourstroma. J Clin Pathol. 2000;53(8):626–9.

  28. Raica M, Cimpean AM, Ribatti D. Angiogenesis in pre-malignant conditions. Eur J Cancer. 2009 Jul;45(11):1924–34.

    Article  CAS  PubMed  Google Scholar 

  29. Redston M. Epithelial neoplasm of the large intestine. In: Odze RD, Goldblum JR, Crawford JM (eds). Surgical pathology of the GI tract, liver, biliary tract, and pancreas. Philadelphia: Saunders; 2004. p. 441–472

  30. Saad RS, Jasnosz KM, Silverman JF. Endoglin (CD105) expression in endometrial carcinoma. Int J Gynecol Pathol. 2003;22:248–53.

    Article  PubMed  Google Scholar 

  31. Saad RS, Liu YL, Nathan G, et al. Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in colorectal cancer. Mod Pathol. 2004 Feb;17(2):197–203.

    Article  CAS  PubMed  Google Scholar 

  32. Saad RS, El-Gohary YL, Memari E, Liu YL, Silverman JF. Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in esophageal adenocarcinoma. Hum Pathol. 2005;36:955–61.

    Article  CAS  PubMed  Google Scholar 

  33. Schoenleber SJ, Kurtz DM, Talwalkar JA, Roberts LR, et al. Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis. Br J Cancer. 2009;100:1385–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Soumaoro LT, Uetake H, Higuchi T, Takagi Y, et al. Cyclooxygenase-2 expression: a significant prognostic indicator for patients with colorectal cancer. Clin Cancer Res. 2004;10:8465–71.

    Article  CAS  PubMed  Google Scholar 

  35. Takahashi N, Kawanishi-Tabata R, Haba A, et al. Association of serum endoglin with metastasis in patients with colorectal, breast, and other solid tumors, and suppressive effect of chemotherapy on the serum endoglin. Clin Cancer Res. 2001;7(3):524–32.

    CAS  PubMed  Google Scholar 

  36. Tien YW, Chang KJ, Jeng M, et al. Tumor angiogenesis and its possible role in intravasation of colorectal epithelial cells. Clin Cancer Res. 2001;7(6):1627–32.

    CAS  PubMed  Google Scholar 

  37. Uribarrena AR, Ortego J, Fuentes J, et al. Prognostic value of microvascular density in Dukes A and B (T1–T4, N0, M0) colorectal carcinomas. Gastroenterol Res Pract. 2009;2009:679830.

    Article  Google Scholar 

  38. Wang Y, Yao X, Ge J, et al. Can vascular endothelial growth factor and microvessel density be used as prognostic biomarkers for colorectal cancer? A systematic review and meta-analysis. Sci World J. 2014:102736.

  39. Weidner N. Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat. 1995;36:169–80.

    Article  CAS  PubMed  Google Scholar 

  40. World Health Organization. International Agency for Research on Cancer. Colorectal Cancer: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. International Agency for Research on Cancer. Available at http://globocan.iarc.fr/Pages/fact_sheets_cance r.aspx. Accessed July 1, 2014.

Download references

Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Author information

Authors and Affiliations

  1. Internal Medicine Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt

    Salem Y. Mohamed

  2. Pathology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt

    Hanan Lotfy Mohammed & Hanaa M. Ibrahim

  3. Radiology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt

    Mohamed Elshaimaa M.

  4. Medical Oncology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt

    Mona Salah

Authors
  1. Salem Y. Mohamed
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hanan Lotfy Mohammed
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hanaa M. Ibrahim
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mohamed Elshaimaa M.
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mona Salah
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Salem Y. Mohamed.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mohamed, S.Y., Mohammed, H.L., Ibrahim, H.M. et al. Role of VEGF, CD105, and CD31 in the Prognosis of Colorectal Cancer Cases. J Gastrointest Canc 50, 23–34 (2019). https://doi.org/10.1007/s12029-017-0014-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12029-017-0014-y

Keywords

Search

Navigation